This reports provides a data-driven overview of the current and future competitive landscape in Sjogren's Syndrome therapeutics.
Key Highlights
In 2022, there will be more than 3.9 million diagnosed prevalence cases of Sjogren's Syndrome across 16 pharmaceutical markets.
No FDA-approved marketed drugs have been available for Sjogren's Syndrome in the last two decades.
The Sjogren's Syndrome pipeline consists of 49 pharmaceuticals spanning all stages of development, with approximately 36% of drugs in mid- to late-stage development.
Commercial sponsors dominate clinical trial development in Sjogren's Syndrome, with the US emerging as the key countries for conducting trials in Sjogren's Syndrome.
Deals involving partnerships were the most common type of deals globally.
Therapeutic options for Sjogren's Syndrome patients continue to be limited as only two new product approvals are expected within the next 5 years.
Scope
The publisher's Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Molecule Type and Route of Administration
Product Profiles with Sales Forecast
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Sjogren's Syndrome market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Sjogren's Syndrome market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Preface
1.1 Contents 1.2 Report Scope 1.3 List of Tables and Figures 1.4 Abbreviations
5.1 Late-stage Pipeline Drugs 5.2 Overview by Development Stage 5.3 Overview by Mechanism of Action 5.4 Overview by Route of Administration 5.5 Overview by Molecule Type 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) 5.7 Therapy Area and Indication-specific PTSR and LoA
6 Clinical Trials Assessment
6.1 Historical Overview 6.2 Overview by Phase 6.3 Overview by Status 6.4 Overview by Phase for Ongoing and Planned Trials 6.5 Trials with Virtual Components 6.6 Geographic Overview 6.7 Single-Country and Multinational Trials by Region 6.8 Top 20 Sponsors with Breakdown by Phase 6.9 Top 20 Sponsors with Breakdown by Status 6.10 Overview by Endpoint Status 6.11 Overview by Race and Ethnicity 6.12 Enrollment Data 6.13 Top 20 countries for Trial Sites 6.14 Top 20 Sites Globally 6.15 Feasibility Analysis - Geographic Overview 6.16 Feasibility Analysis - Benchmark Models
7 Deals Landscape
7.1 Mergers, Acquisitions, and Strategic Alliances by Region 7.2 Recent Mergers, Acquisitions, and Strategic Alliances
8 Commercial Assessment
8.1 Key Market Players
9 Future Market Catalysts
10 Appendix
10.1 Methodology 10.2 Methodology - PTSR and LoA Analysis 10.3 About the Authors 10.4 Contact the Publisher 10.5 Disclaimer
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
*Required Information
This website uses cookies to ensure you get the best experience. Learn more